Curated News
By: NewsRamp Editorial Staff
November 09, 2026
GeoVax Labs Sets 1-for-24 Reverse Stock Split to Regain Nasdaq Compliance
TLDR
- GeoVax's 1-for-24 reverse split aims to regain Nasdaq compliance, preserving listing and investor access to its vaccine and cancer programs.
- GeoVax will convert every 24 shares into one share effective November 11, 2026, reducing outstanding shares to about 508,745 while keeping ownership percentages unchanged.
- GeoVax's reverse split supports continued development of vaccines for mpox and smallpox and therapies for cancer, aiming to improve global health.
- GeoVax's reverse stock split will automatically convert 24 shares into one, leaving fractional shares rounded to the nearest whole number.
Impact - Why it Matters
This reverse stock split is a critical step for GeoVax to maintain its Nasdaq listing, which is essential for accessing public capital to advance its pipeline. Without compliance, the company risks delisting, which could severely limit its ability to fund the planned Phase 3 trial of GEO-MVA and the development of Gedeptin®. For investors, the split preserves ownership percentages but reduces the number of shares, often a precursor to further financing or strategic moves. The news underscores the financial pressures facing clinical-stage biotechs and the importance of regulatory milestones in sustaining investor confidence.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced that its Board of Directors has approved a 1-for-24 reverse stock split of its common stock. The move is intended to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Stockholders approved the split at a meeting on October 27, 2026. The reverse stock split will become effective at 12:01am ET on November 11, 2026, and the common stock is expected to begin trading on a split-adjusted basis at the market open, continuing under the symbol “GOVX” with a new CUSIP number 373678 804.
On the effective date, every 24 issued and outstanding shares will automatically convert into one share, reducing the total outstanding shares from 12,209,871 to approximately 508,745. Each stockholder’s percentage ownership and voting power will remain unchanged, except for minor adjustments due to rounding of fractional shares. The rights and privileges of common stockholders will be substantially unaffected. GeoVax’s priority program is GEO-MVA, an MVA-based vaccine targeting mpox and smallpox, advancing under an expedited regulatory pathway with a planned pivotal Phase 3 trial in late 2026. In oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity, which has completed a Phase 1/2 trial in advanced head and neck cancer. For more information, visit www.geovax.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, GeoVax Labs Sets 1-for-24 Reverse Stock Split to Regain Nasdaq Compliance
